Regional Stocks
Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Search InvestCenter
Recent Quotes
My Watchlist
Indicators
Halozyme Therapeutics, Inc. (NQ: HALO)
7.420 USD  -0.030 (-0.40%)
Official Closing Price  /  Updated: 8:10 PM EDT, May 24, 2013  /  Add to My Watchlist      
View: Quote News Research
Press releases about Halozyme Therapeutics, Inc.
 
< Previous 1 2 3 4 5 6 7 8 9 Next >
Halozyme Therapeutics And Pfizer Enter Into A Collaboration To Develop And Commercialize Subcutaneous Biologics Using Recombinant Human Hyaluronidase
December 21, 2012
from PR Newswire
ViroPharma and Halozyme Therapeutics Announce Initiation of Phase 2b Dose Ranging Combination Study for Subcutaneous Administration of Cinryze® (C1 esterase inhibitor [human]) With Hyaluronidase (rHuP
December 19, 2012
from PR Newswire
Halozyme Announced Roche Filed A Marketing Authorization Application For Subcutaneous MabThera
December 08, 2012
Filing Triggered a $4 Million Milestone Payment to Halozyme From Roche Read More
from PR Newswire
Higher Rate of FDA New Drug Approvals a Major Factor in Biotech Industry's Success in 2012
December 03, 2012
Five Star Equities Provides Stock Research on Halozyme Therapeutics and Merrimack Pharmaceuticals Read More
from Marketwired News Releases
Halozyme Reports Third Quarter 2012 Financial Results
November 08, 2012
from PR Newswire
Halozyme Therapeutics To Present At The Lazard Capital Markets 9th Annual Healthcare Conference
November 06, 2012
from PR Newswire
Halozyme to Host Third Quarter Financial Results Conference Call
November 01, 2012
from PR Newswire
FDA Considering Allowing Developers of Critical Drugs/Treatments to Conduct Smaller, Faster Clinical Trials
October 30, 2012
The Paragon Report Provides Stock Research on Achillion Pharmaceuticals and Halozyme Therapeutics Read More
from Marketwired News Releases
Biotech Industry Applauds the Introduction of the High Technology Small Business Research Incentives Act
October 08, 2012
Five Star Equities Provides Stock Research on Exelixis and Halozyme Therapeutics Read More
from Marketwired News Releases
Halozyme Therapeutics to Host Analyst / Investor Meeting on October 2nd in New York
September 25, 2012
from PR Newswire
ViroPharma And Halozyme Provide Update On Clinical Development Of Subcutaneous Cinryze® (C1 Esterase Inhibitor [Human]) With Recombinant Human Hyaluronidase (rHuPH20)
September 21, 2012
from PR Newswire
Faster FDA Review Process Contributing to Biotech Industry's Success in 2012
September 19, 2012
The Paragon Report Provides Stock Research on Halozyme Therapeutics and XOMA Read More
from Marketwired News Releases
Biotech Industry Merger and Acquisition Activity at a Four-Year High as Pharmaceuticals Look to Offset Patent Cliffs
August 29, 2012
Five Star Equities Provides Stock Research on Halozyme Therapeutics and PDL BioPharma Read More
from Marketwired News Releases
Halozyme Therapeutics and Zalicus Recent Movers in a Booming Industry
August 09, 2012
The Paragon Report Provides Stock Research on Halozyme Therapeutics and Zalicus Read More
from Marketwired News Releases
Halozyme Reports Second Quarter 2012 Financial Results
August 06, 2012
from PR Newswire
Halozyme to Host Second Quarter Financial Results Conference Call
August 02, 2012
from PR Newswire
Halozyme Confirms Baxter Has Received A Complete Response Letter For HyQ BLA
August 01, 2012
Company to Host Conference Call Providing Regulatory Update on Plasma-Derived Subcutaneous Programs Read More
from PR Newswire
Halozyme's Ultrafast Insulin Formulations Improved Postprandial Glycemic Control in Patients Living with Type 1 Diabetes: Phase 2 Study Results Presented at ADA 2012
June 11, 2012
Superior Control of Mealtime Glucose Significantly Reduced Hypoglycemia Read More
from PR Newswire
Interim Data From Pre-administration of Hylenex in Analog Insulin Pump Therapy Demonstrate Consistent Insulin Action Profile: Data Presented in Late-Breaker Poster at ADA 2012
June 09, 2012
Improved Glucose Control Read More
from PR Newswire
Halozyme Presents Positive Data from Two Ultrafast Insulin Clinical Trials with Human Hyaluronidase Enzyme - rHuPH20 - at ADA 2012
June 09, 2012
Analog-PH20 Improved Postprandial Glycemic Control in Patients with Type 2 Diabetes Read More
from PR Newswire
Halozyme Therapeutics to Present New Data on the Company's Ultrafast Insulin Programs at ADA 2012
June 01, 2012
from PR Newswire
Halozyme Therapeutics to Present at the Jefferies 2012 Global Healthcare Conference
May 31, 2012
from PR Newswire
Halozyme Therapeutics to Present at the Bank of America Merrill Lynch 2012 Health Care Conference
May 09, 2012
from PR Newswire
Halozyme Reports First Quarter 2012 Financial Results
May 07, 2012
from PR Newswire
Halozyme to Host First Quarter 2012 Financial Results Conference Call
April 30, 2012
from PR Newswire
Baxter and Halozyme Provide Update on HyQ Biologics License Application
April 16, 2012
from Business Wire News Releases
Baxter and Halozyme Provide Update on HyQ Biologics License Application
April 16, 2012
from PR Newswire
Human Genome Sciences, Inc. and Halozyme Therapeutics, Inc. Future Looks Promising With Senate Passing of JOBS Act
March 30, 2012
The Paragon Report Provides Stock Research on Human Genome Sciences, Inc. and Halozyme Therapeutics, Inc. Read More
from Marketwired News Releases
Halozyme Reports Fourth Quarter and Year End 2011 Financial Results and Provides Guidance for 2012
March 09, 2012
Company Announces Roche Submission of a Line Extension Application for Subcutaneous Herceptin, Triggering a $4 Million Milestone Payment Read More
from PR Newswire
Halozyme Therapeutics to Present at Two Upcoming Investor Conferences in March
March 07, 2012
from PR Newswire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here